CA3131294A1 - Quinazolinone compounds - Google Patents

Quinazolinone compounds Download PDF

Info

Publication number
CA3131294A1
CA3131294A1 CA3131294A CA3131294A CA3131294A1 CA 3131294 A1 CA3131294 A1 CA 3131294A1 CA 3131294 A CA3131294 A CA 3131294A CA 3131294 A CA3131294 A CA 3131294A CA 3131294 A1 CA3131294 A1 CA 3131294A1
Authority
CA
Canada
Prior art keywords
compound
ome
hydrogen
alkyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3131294A
Other languages
English (en)
French (fr)
Inventor
Bingwei Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cerepeut LLC
Original Assignee
Cerepeut LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerepeut LLC filed Critical Cerepeut LLC
Publication of CA3131294A1 publication Critical patent/CA3131294A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3131294A 2019-02-27 2020-02-26 Quinazolinone compounds Pending CA3131294A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962811471P 2019-02-27 2019-02-27
US62/811,471 2019-02-27
PCT/US2020/019942 WO2020176652A1 (en) 2019-02-27 2020-02-26 Quinazolinone compounds

Publications (1)

Publication Number Publication Date
CA3131294A1 true CA3131294A1 (en) 2020-09-03

Family

ID=72238692

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3131294A Pending CA3131294A1 (en) 2019-02-27 2020-02-26 Quinazolinone compounds

Country Status (9)

Country Link
US (1) US12454514B2 (https=)
EP (1) EP3930837A4 (https=)
JP (1) JP7597722B2 (https=)
KR (1) KR20210139279A (https=)
CN (1) CN113747943A (https=)
AU (1) AU2020228374A1 (https=)
CA (1) CA3131294A1 (https=)
IL (1) IL285805A (https=)
WO (1) WO2020176652A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024033374A1 (en) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Novel arylcarboxamide or arylthioamide compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07107056B2 (ja) * 1987-01-30 1995-11-15 日清製粉株式会社 ４（３ｈ）−キナゾリノン誘導体、その製造方法およびそれを有効成分とする抗潰瘍剤
US7381730B2 (en) * 2002-03-15 2008-06-03 Bristol-Myers Squibb Company 3-arylquinazoline derivatives as selective estrogen receptor beta modulators
US20050038051A1 (en) * 2003-06-09 2005-02-17 Jodi Nunnari Novel molecules for regulating cell death
US9492450B2 (en) * 2011-04-19 2016-11-15 University of Pittsburgh—of the Commonwealth System of Higher Education Inhibition of dynamin related protein 1 to promote cell death
WO2013025508A1 (en) * 2011-08-12 2013-02-21 Southern Research Institute Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections
JP2013142070A (ja) 2012-01-11 2013-07-22 Nihon Univ ミトコンドリア分裂阻害剤を用いたｔｒａｉｌ抵抗性の克服
CN111372921B (zh) * 2017-09-13 2023-12-01 赛勒佩特公司 小分子化合物
US11559527B2 (en) 2017-12-20 2023-01-24 Lunella Biotech, Inc. Targeting mitochondrial fission through mDIVI-1 derivatives
US20190307749A1 (en) * 2018-04-10 2019-10-10 Texas Tech University System Mitochondria-Division Inhibitor 1 Protects Against Amyloid-B Induced Mitochondrial Fragmentation and Synaptic Damage in Alzheimer's Disease

Also Published As

Publication number Publication date
US20220162172A1 (en) 2022-05-26
US12454514B2 (en) 2025-10-28
AU2020228374A1 (en) 2021-09-23
WO2020176652A1 (en) 2020-09-03
EP3930837A4 (en) 2022-10-05
KR20210139279A (ko) 2021-11-22
IL285805A (en) 2021-10-31
JP2022523383A (ja) 2022-04-22
CN113747943A (zh) 2021-12-03
JP7597722B2 (ja) 2024-12-10
EP3930837A1 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
TWI891621B (zh) 一種噠嗪類衍生物抑制劑、其製備方法和應用
JP5204486B2 (ja) シクロパミンアナログ及びその使用方法
CN109665968A (zh) 并环化合物及其制备方法和用途
KR20100017768A (ko) 플루오렌, 안트라센, 잔텐, 디벤조수베론 및 아크리딘의 유도체 및 이의 용도
HUP0203238A2 (hu) Hatóanyagok rosszindulatú daganatok kezelésére, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
CN112654622A (zh) 并环化合物、其制备方法及用途
CA3152508A1 (en) Perk inhibiting pyrrolopyrimidine compounds
WO2012142615A2 (en) Auranofin and auranofin analogs useful to treat proliferative disease and disorders
US12404251B2 (en) Small molecule compound
CA3131294A1 (en) Quinazolinone compounds
WO2013052465A1 (en) [1,3]dioxolo[4,5-g]quinoline-6(5h)thione and [1,3]dioxolo[4,5-g][1,2,4]triazolo[1,5-a]quinoline derivatives as inhibitors of the late sv40 factor (lsf) for use in treating cancer
CN109206435B (zh) 噻吩并[3,2-d]嘧啶类化合物及其制备方法和医药用途
US9334280B2 (en) Synthetic rigidin analogues as anticancer agents, salts, solvates and prodrugs thereof, and method of producing same
WO2016127949A1 (zh) 作为t790变异抑制剂的嘧啶衍生物
KR101495834B1 (ko) 신규한 1,2-디페닐에탄 유도체 및 이의 안드로겐 수용체 조절 효과
CN114599662B (zh) 基于新霉素的化合物及其药物用途
KR102109869B1 (ko) 7-아자인돌린-2-온 유도체 또는 이의 약제학적 허용가능한 염을 유효성분으로 함유하는 약학 조성물
US20260028364A1 (en) Cationic chromenones and their use in oncology
WO2022162025A1 (en) Heteroaromatic phosphonium salts and their use treating cancer
CN111253390A (zh) 并环化合物、其制备方法及用途
WO2019141095A1 (zh) 脒类和胍类衍生物、其制备方法及其在医药上的应用
HK1257006B (en) Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231106

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241122

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241206

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241206

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250324

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251202

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251202